Cytomegalovirus igg elisa kit

Kenya Cohort: Blood samples were collected from individuals ≥18 years of age enrolled at the Kenya Medical Research Institute Clinical Research Center in Kisumu, Kenya. Study participants included adults with a normal chest x-ray and no symptoms of TB disease and no previous history of diagnosis or treatment for active TB disease. Mtb infection status was evaluated by QuantiFERON®-TB Gold In-Tube (QFT; Qiagen). Individuals with a positive QFT result (TB Antigen-Nil ≥0.35 IU/ml) were defined as having LTBI. Individuals with a TB Antigen-Nil response <0.35 IU/ml were defined as healthy controls (QFT⁻). Serologic testing for HIV antibodies was done for all individuals using the Diagnostic Kit for HIV (1+2) Antibody V2 (KHB® Shanghai Kehua Bio-engineering Co., Ltd). All participants enrolled for the study were seronegative for HIV. HCMV seropositivity in healthy Kenyan adults is 97% (Njeru et al., 2009 (link)), thus participants enrolled in Kisumu are presumed to be HCMV seropositive. U.S. healthy controls: Blood samples were collected from healthy adults enrolled at the Emory Vaccine Center in Atlanta, GA. U.S. healthy adult controls were U.S.-born, had not been vaccinated with BCG, and had no history of exposure to TB. All U.S. healthy controls were seropositive for HCMV IgG antibodies, as measured using the Cytomegalovirus IgG ELISA kit (Abnova).